首頁 > 市場調查報告書 > 製藥

疫苗感染疾病

市場調查報告書

商品編碼

1348917

瘧疾疫苗市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按疫苗類型、管理途徑、地區和競爭細分

Malaria Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Vaccine Type, By Route of Administration, Region and Competition

出版日期: 2023年08月01日 | 出版商:

TechSci Research | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球瘧疾疫苗市場在 2024-2028 年預測期內將出現令人印象深刻的成長。這可以歸因於瘧疾盛行率的增加、研發活動的增加以及醫療基礎設施投資的增加。瘧疾是許多發展中國家，特別是撒哈拉以南非洲國家的一個主要公共衛生問題。這種疾病的沉重負擔產生了對有效瘧疾疫苗的強烈需求。這導致了對開發可以預防瘧疾感染或減輕其嚴重程度的疫苗的大量投資。根據最新的《世界瘧疾報告》，2021 年有 2.47 億例瘧疾病例，高於 2020 年的 2.45 億例。與 2020 年的 625,000 人相比，2021 年與瘧疾相關的死亡人數預計為 619, 000 人。

生物技術的進步大大加速了瘧疾疫苗的開發。近年來，人們對瘧疾感染的分子和細胞機制有了更深入的了解，從而確定了潛在的候選疫苗。此外，DNA疫苗和病毒載體疫苗等疫苗開發技術的進步，使得能夠創造出更有效、更安全的瘧疾疫苗，為未來幾年全球瘧疾疫苗市場的成長開闢了新的前景。

市場概況
預測期	2024-2028
2022 年市場規模	40102萬美元
2028 年市場規模	5.2919億美元
年複合成長率	4.6%
成長最快的細分市場	前紅血球
最大的市場	中東和非洲

瘧疾盛行率增加

瘧疾盛行率的不斷上升是全球瘧疾疫苗市場的主要驅動力之一。瘧疾是一種危及生命的疾病，由瘧原蟲寄生蟲引起，透過受感染的蚊子叮咬傳播給人類。世界衛生組織預計，到 2021 年，全球近一半人口將面臨瘧疾威脅。預計 2021 年將有 619 000 人死於瘧疾。世衛組織非洲區域承擔了全球瘧疾負擔的很大一部分。 2021 年，95% 的瘧疾病例和 96% 的瘧疾死亡發生在該區域。在該區域，80% 的瘧疾死亡病例是五歲以下兒童。瘧疾的高發病率導致對開發新療法和預防措施（包括疫苗）的投資增加。瘧疾疫苗有可能成為對抗這種疾病的重要工具，特別是在其他干涉措施可能效果較差的高負擔地區。瘧疾的日益普及也導致製藥公司和非營利組織增加了研發投資。這導致了新候選疫苗的開發以及現有疫苗在新人群中的測試。

加強研究與開發

不斷增加的研發（R＆D）活動是全球瘧疾疫苗市場成長的關鍵驅動力。開發有效的瘧疾疫苗對於減輕這種致命疾病的負擔至關重要，特別是在瘧疾最流行的低收入和中等收入國家。撒哈拉以南非洲和世界其他地區的瘧疾發生率較高，導致對新疫苗開發的投資增加。許多製藥公司、學術機構和非營利組織正在致力於開發新的瘧疾疫苗並改進現有疫苗。全球瘧疾疫苗市場的研發活動集中在幾個領域，包括新疫苗標靶的確定、新型疫苗輸送系統的開發以及新候選疫苗的臨床試驗測試。全球瘧疾疫苗市場不斷增加的研發活動得到了政府資金、私人投資和慈善捐贈的支持。例如，比爾和梅琳達蓋茲基金會為瘧疾疫苗的研發提供了大量資金，包括支持 Mosquirix 疫苗的開發。

增加投資

增加對開發和改善醫療基礎設施的投資是全球瘧疾疫苗市場成長的另一個重要驅動力。開發有效的瘧疾疫苗只是對抗這種疾病的解決方案的一部分。同樣重要的是建立強大的醫療基礎設施，可以有效地向有需要的人提供疫苗。在瘧疾最流行的許多低收入和中等收入國家，醫療基礎設施往往不足或根本不存在，導致難以有效提供疫苗和其他基本醫療服務。增加對醫療保健基礎設施的投資可以透過提高包括疫苗在內的醫療保健服務的可用性和可近性來幫助解決這個問題。這包括對醫療設施、醫療設備、醫療人員和醫療物流的投資。例如，投資建造新的醫療保健設施，如診所和醫院，可以幫助擴大服務不足地區獲得醫療保健服務的機會。對冰箱和冰櫃等醫療設備的投資有助於確保疫苗正確儲存並保持有效性。政府和私部門資金都支持增加對醫療基礎設施的投資。增加對醫療保健基礎設施的投資，透過提高包括疫苗在內的醫療保健服務的可用性和可近性，正在推動全球瘧疾疫苗市場的成長。

最新進展：

這種名為 R21/Matrix-M 的瘧疾疫苗由印度血清研究所生產，已獲得加納政府批准在該國使用。這標誌著抗擊瘧疾的鬥爭向前邁出了重要一步，瘧疾是加納和其他撒哈拉以南非洲國家的一個主要公共衛生問題。

Mosquirix 是一種疫苗，旨在預防惡性瘧原蟲（最致命的瘧疾寄生蟲）。該疫苗由葛蘭素史克 (GSK) 與 PATH 瘧疾疫苗計劃合作開發，已獲得歐洲藥品管理局 (EMA) 批准使用。

CVac 是一種全寄生蟲瘧疾疫苗，利用基因改造寄生蟲刺激免疫反應。 2021年，諾華宣布完成了CVac疫苗的1期臨床試驗，結果顯示該疫苗在健康志願者中是安全且耐受性良好的。該公司計劃推進二期臨床試驗以評估疫苗的功效。

2021年，印度血清研究所宣布與牛津大學合作開發一種新的以mRNA為基礎的瘧疾疫苗。該疫苗將使用與開發 Pfizer-BioNTech 和 Moderna COVID-19 疫苗相同的技術。與傳統疫苗相比，mRNA 疫苗有可能提供更有效的免疫反應。

市場區隔：

全球瘧疾疫苗市場可以按疫苗類型、給藥途徑和地區進行細分。根據疫苗類型，全球瘧疾疫苗市場可分為紅血球前疫苗、紅血球疫苗、多抗原疫苗和其他疫苗。根據給藥途徑，全球瘧疾疫苗市場分為肌肉內、皮下、皮內和其他。從地區來看，瘧疾疫苗市場可分為北美、歐洲、亞太地區、南美洲以及中東和非洲。

市場參與者

GlaxoSmithKline, Plc.、Novartis AG、Takeda Pharmaceutical Company、Sanaria Inc.、Merck & Co、Johnson & Johnson、Pfizer Inc.、Serum Institute of India Private Limited、Bharat Biotech International Limited、Moderna Inc 是營運中的一些領先參與者在全球瘧疾疫苗市場。

報告範圍：

在本報告中，除了以下詳細介紹的產業趨勢外，全球瘧疾疫苗市場也分為以下幾類：

全球瘧疾疫苗市場，依疫苗類型：

前紅血球

紅血球

多抗原

其他

全球瘧疾疫苗市場（依給藥途徑）：

肌肉注射

皮下

皮內

其他

全球瘧疾疫苗市場（按地區）：

北美洲

美國

加拿大

墨西哥

歐洲

德國

英國

法國

義大利

西班牙

亞太地區

印度

日本

韓國

澳洲

越南

印尼

緬甸

南美洲

巴西

哥倫比亞

中東和非洲

南非

沙烏地阿拉伯

阿拉伯聯合大公國

埃及

土耳其

奈及利亞

競爭格局

公司概況：全球瘧疾疫苗市場主要公司的詳細分析。

可用的客製化：

根據給定的市場數據，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

其他市場參與者（最多五個）的詳細分析和概況分析。

Global Malaria Vaccine Market will witness an impressive growth during the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of malaria, growing R&D activities and increasing investment in healthcare infrastructure. Malaria is a major public health problem in many developing countries, particularly in sub-Saharan Africa. The high burden of the disease has created a strong demand for effective malaria vaccines. This has led to significant investment in the development of vaccines that can prevent malaria infection or reduce its severity. In 2021, there were 247 million cases of malaria, up from 245 million cases in 2020, according to the most recent World Malaria Report. Compared to 625,000 in 2020, the expected number of malaria-related deaths was 619, 000 in 2021.

Advancements in biotechnology have significantly accelerated the development of malaria vaccines. In recent years, there has been a greater understanding of the molecular and cellular mechanisms involved in malaria infection, which has led to the identification of potential vaccine candidates. Additionally, advances in vaccine development technologies, such as DNA vaccines and viral vector-based vaccines, have allowed for the creation of more effective and safer malaria vaccines, thereby opening new prospects for the growth of global malaria vaccine market in the next few years.

The growth of the malaria vaccine market faces several challenges, including scientific complexities due to the complex nature of the malaria parasite and its ability to mutate rapidly, financial constraints in terms of research and development costs, regulatory hurdles for approval and distribution, limited infrastructure in some regions for effective vaccine distribution, and the growing trend of vaccine hesitancy and political instability in malaria-endemic areas. Developing a vaccine requires approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This process can be lengthy and expensive, and the requirements for approval can be stringent, making it difficult for smaller companies to navigate the process.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 401.02 Million
Market Size 2028	USD 529.19 Million
CAGR	4.6%
Fastest Growing Segment	Pre-Erythrocytic
Largest Market	Middle East & Africa

Increasing Prevalence of Malaria

The growing prevalence of malaria is one of the key drivers of the global malaria vaccine market. Malaria is a life-threatening disease that is caused by the Plasmodium parasite, which is transmitted to humans through the bite of infected mosquitoes. Nearly half of the world's population was predicted to be in danger of malaria in 2021 by WHO. 619 000 deaths from malaria were anticipated in 2021. A disproportionately large amount of the worldwide malaria burden is placed on the WHO African Region. 95% of malaria cases and 96% of malaria deaths occurred in the Region in 2021. In the region, 80% of all malaria deaths were in children under the age of five. The high prevalence of malaria has led to increased investment in the development of new treatments and preventive measures, including vaccines. Malaria vaccines have the potential to be an important tool in the fight against the disease, particularly in high-burden areas where other interventions may be less effective. The growing prevalence of malaria has also led to increased investment in research and development by pharmaceutical companies and non-profit organizations. This has led to the development of new vaccine candidates and the testing of existing vaccines in new populations.

Increasing Research & Development

Increasing research and development (R&D) activities are a key driver of the growth of the global malaria vaccine market. The development of effective malaria vaccines is critical to reducing the burden of this deadly disease, particularly in low- and middle-income countries where malaria is most prevalent. The high incidence of malaria in sub-Saharan Africa and other parts of the world has led to increased investment in the development of new vaccines. Many pharmaceutical companies, academic institutions, and non-profit organizations are working on developing new malaria vaccines and improving existing ones. R&D activities in the global malaria vaccine market are focused on several areas, including the identification of new vaccine targets, the development of novel vaccine delivery systems, and the testing of new vaccine candidates in clinical trials. Increasing R&D activities in the global malaria vaccine market have been supported by government funding, private investment, and philanthropic donations. For instance, the Bill and Melinda Gates Foundation has provided significant funding for malaria vaccine research and development, including support for the development of the Mosquirix vaccine.

Increasing Investments

Increasing investment in developing and improvising healthcare infrastructure is another important driver of the growth of the global malaria vaccine market. The development of effective malaria vaccines is only one part of the solution to combating this disease. Equally important is the establishment of a strong healthcare infrastructure that can effectively deliver vaccines to those who need them. In many low- and middle-income countries where malaria is most prevalent, healthcare infrastructure is often inadequate or nonexistent, making it difficult to effectively deliver vaccines and other essential healthcare services. Increasing investment in healthcare infrastructure can help to address this problem by improving the availability and accessibility of healthcare services, including vaccines. This includes investment in healthcare facilities, medical equipment, healthcare personnel, and healthcare logistics. For instance, investment in the construction of new healthcare facilities, such as clinics and hospitals, can help to expand access to healthcare services in underserved areas. Investment in medical equipment, such as refrigerators and freezers, can help to ensure that vaccines are stored properly and remain effective. Increased investment in healthcare infrastructure has been supported by both government and private sector funding. Increasing investment in healthcare infrastructure is driving the growth of the global malaria vaccine market by improving the availability and accessibility of healthcare services, including vaccines.

Recent Developments:

The malaria vaccine, known as R21/Matrix-M, which is manufactured by the Serum Institute of India, has received clearance from the Ghanaian government to be used in the country. This marks a significant step forward in the fight against malaria, which is a major public health problem in Ghana and other sub-Saharan African countries.

Mosquirix is a vaccine that is designed to provide protection against Plasmodium falciparum, the deadliest species of malaria parasite. The vaccine was developed by GlaxoSmithKline (GSK) in partnership with the PATH Malaria Vaccine Initiative, and it has been approved for use by the European Medicines Agency (EMA).

CVac is a whole-parasite malaria vaccine that uses genetically modified parasites to stimulate an immune response. In 2021, Novartis announced that it had completed a Phase 1 clinical trial of the CVac vaccine, which showed that the vaccine was safe and well-tolerated in healthy volunteers. The company plans to move forward with Phase 2 clinical trials to evaluate the efficacy of the vaccine.

In 2021, Serum Institute of India announced that it had partnered with the University of Oxford to develop a new mRNA-based malaria vaccine. The vaccine will use the same technology that was used to develop the Pfizer-BioNTech and Moderna COVID-19 vaccines. The mRNA vaccine has the potential to provide a more effective immune response compared to traditional vaccines.

Market Segmentation:

Global Malaria Vaccine Market can be segmented by vaccine type, by route of administration, and by region. Based on vaccine type, global malaria vaccine market can be divided into Pre-Erythrocytic, Erythrocytic, Multi-antigen, and Others. Based on route of administration, the global malaria vaccine market is divided into Intramuscular, Subcutaneous, Intradermal, and Others. Regionally, the Malaria Vaccine Market can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

GlaxoSmithKline, Plc., Novartis AG, Takeda Pharmaceutical Company, Sanaria Inc., Merck & Co., Johnson & Johnson, Pfizer Inc., Serum Institute of India Private Limited, Bharat Biotech International Limited, Moderna Inc are some of the leading players operating in the Global Malaria Vaccine Market.

Report Scope:

In this report, Global Malaria Vaccine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Malaria Vaccine Market, By Vaccine Type:

Pre-Erythrocytic

Erythrocytic

Multi-antigen

Others

Global Malaria Vaccine Market, By Route of Administration:

Intramuscular

Subcutaneous

Intradermal

Others

Global Malaria Vaccine Market, By Region:

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Asia Pacific

India

Japan

South Korea

Australia

Vietnam

Indonesia

Myanmar

South America

Brazil

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Turkey

Nigeria

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Malaria Vaccine Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malaria Vaccine Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others)
- 5.2.2. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2022)
5.3. Product Map
- 5.3.1. By Vaccine Type
- 5.3.2. By Route of Administration
- 5.3.3. By Region

6. North America Malaria Vaccine Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Vaccine Type
- 6.2.2. By Route of Administration
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Malaria Vaccine Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Vaccine Type
    - 6.3.1.2.2. By Route of Administration
- 6.3.2. Canada Malaria Vaccine Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Vaccine Type
    - 6.3.2.2.2. By Route of Administration
- 6.3.3. Mexico Malaria Vaccine Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Vaccine Type
    - 6.3.3.2.2. By Route of Administration

7. Europe Malaria Vaccine Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Vaccine Type
- 7.2.2. By Route of Administration
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Malaria Vaccine Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Vaccine Type
    - 7.3.1.2.2. By Route of Administration
- 7.3.2. Germany Malaria Vaccine Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Vaccine Type
    - 7.3.2.2.2. By Route of Administration
- 7.3.3. United Kingdom Malaria Vaccine Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Vaccine Type
    - 7.3.3.2.2. By Route of Administration
- 7.3.4. Italy Malaria Vaccine Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Vaccine Type
    - 7.3.4.2.2. By Route of Administration
- 7.3.5. Spain Malaria Vaccine Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Vaccine Type
    - 7.3.5.2.2. By Route of Administration

8. Asia-Pacific Malaria Vaccine Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Vaccine Type
- 8.2.2. By Route of Administration
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. India Malaria Vaccine Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Vaccine Type
    - 8.3.1.2.2. By Route of Administration
- 8.3.2. Japan Malaria Vaccine Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Vaccine Type
    - 8.3.2.2.2. By Route of Administration
- 8.3.3. South Korea Malaria Vaccine Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Vaccine Type
    - 8.3.3.2.2. By Route of Administration
- 8.3.4. Australia Malaria Vaccine Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Vaccine Type
    - 8.3.4.2.2. By Route of Administration
- 8.3.5. Indonesia Malaria Vaccine Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Vaccine Type
    - 8.3.5.2.2. By Route of Administration
- 8.3.6. Vietnam Malaria Vaccine Market Outlook
  - 8.3.6.1. Market Size & Forecast
    - 8.3.6.1.1. By Value
  - 8.3.6.2. Market Share & Forecast
    - 8.3.6.2.1. By Vaccine Type
    - 8.3.6.2.2. By Route of Administration
- 8.3.7. Myanmar Malaria Vaccine Market Outlook
  - 8.3.7.1. Market Size & Forecast
    - 8.3.7.1.1. By Value
  - 8.3.7.2. Market Share & Forecast
    - 8.3.7.2.1. By Vaccine Type
    - 8.3.7.2.2. By Route of Administration

9. South America Malaria Vaccine Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Vaccine Type
- 9.2.2. By Route of Administration
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Malaria Vaccine Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Vaccine Type
    - 9.3.1.2.2. By Route of Administration
- 9.3.2. Colombia Malaria Vaccine Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Vaccine Type
    - 9.3.2.2.2. By Route of Administration

10. Middle East and Africa Malaria Vaccine Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Vaccine Type
- 10.2.2. By Route of Administration
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Malaria Vaccine Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Vaccine Type
    - 10.3.1.2.2. By Route of Administration
- 10.3.2. Saudi Arabia Malaria Vaccine Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Vaccine Type
    - 10.3.2.2.2. By Route of Administration
- 10.3.3. UAE Malaria Vaccine Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Vaccine Type
    - 10.3.3.2.2. By Route of Administration
- 10.3.4. Egypt Malaria Vaccine Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Vaccine Type
    - 10.3.4.2.2. By Route of Administration
- 10.3.5. Turkey Malaria Vaccine Market Outlook
  - 10.3.5.1. Market Size & Forecast
    - 10.3.5.1.1. By Value
  - 10.3.5.2. Market Share & Forecast
    - 10.3.5.2.1. By Vaccine Type
    - 10.3.5.2.2. By Route of Administration
- 10.3.6. Nigeria Malaria Vaccine Market Outlook
  - 10.3.6.1. Market Size & Forecast
    - 10.3.6.1.1. By Value
  - 10.3.6.2. Market Share & Forecast
    - 10.3.6.2.1. By Vaccine Type
    - 10.3.6.2.2. By Route of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global Malaria Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Business Overview
15.2. Product Offerings
15.3. Recent Developments
15.4. Key Personnel
15.5. SWOT Analysis
- 15.5.1. GlaxoSmithKline, Plc.
- 15.5.2. Novartis AG
- 15.5.3. Takeda Pharmaceutical Company
- 15.5.4. Sanaria Inc.
- 15.5.5. Merck & Co.
- 15.5.6. Johnson & Johnson
- 15.5.7. Pfizer Inc.
- 15.5.8. Serum Institute of India Private Limited
- 15.5.9. Bharat Biotech International Limited
- 15.5.10. Moderna Inc